Cleveland Clinic Lerner Research Institute

We're moving! To continue seeing our research new and updates, follow us on Twitter, LinkedIn, and Instagram.

A collaborative research and clinical team at Cleveland Clinic has identified eltrombopag, currently used for the treatment of Aplastic anemia and chronic immune thrombocytopenia, as a potential therapeutic specific for a certain type of leukemia.

Researchers Find Potential for Repurposing Drug to Target Certain Types of Leukemia Cells Drs. Jha and Maciejewski have identified eltrombopag as a potent inhibitor of specific leukemia cells, which could lead to new drugs that target leukemia cells while preserving and expanding normal blood cells.

A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment.

Flipping the Switch on Prostate Cancer Immunotherapy Dr. Nima Sharifi and a team of researchers uncovered how tumors circumvent prostate cancer therapy and identified a potential window of time after treatment when tumors may be responsive to immunotherapy.

A new study led by Lynn Bekris, PhD, Associate Staff in the Genomic Medicine Institute, suggests that inflammatory activity related to the sTREM2 protein may be linked to Alzheimer’s disease (AD) progression.

Exploring a Blood-Based Biomarker of Inflammation for Alzheimer’s Disease Dr. Bekris’ team found that patterns of sTREM2-related inflammatory activity were specific to Alzheimer’s disease stages.

New grant will provide funding to further Dr. Lathia’s research into understanding how the microenvironment generates and maintains immune suppression to fuel the growth of malignant brain tumors.

Dr. Justin Lathia Named One of Only Nine Recipients of National Research Program Award Dr. Lathia has received an eight-year, $5.2 million award from the National Institute of Neurological Disorders and Stroke to further research into the dynamics of immune suppression in malignant brain tumors and target future immune-activating therapies

Cleveland Clinic researchers are changing the course of history by establishing the Cleveland Clinic Latino Epidemiology (CCLE) Cohort. The cohort will help close the gap in research participation and health disparities for the Latino population.

New Research Collaborative Aims at Closing Minority Health Disparities With a Cleveland Clinic research co-laboratories award, Drs. Schmit and Mata will establish the Cleveland Clinic Latino Epidemiology (CCLE) Cohort to help close the gap in research participation and health disparities for the Latino population.

DNA-damaging therapies for colorectal cancer (CRC) can confer resistance to chemotherapy by promoting nuclear translocation of the protein myeloid cell leukemia (MCL1). Evidence suggests that this chemoresistance may be overcome by co-treating the disease with Bcl-xL inhibitors.

MCL1 in the Nucleus Appears to Drive Chemoresistance in Colorectal Cancer Dr. Gastman and collaborators have published findings indicating Bcl-xL inhibitors may help overcome this complication.

The Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium has received a 3-year, $5.3 million award from the Leona M. and Harry B. Helmsley Charitable Trust to expand its support for the development of a next generation biomarker tool for Crohn’s disease patients with intestinal fibrosis. The award will be split among Cleveland Clinic, Mayo Clinic and Alimentiv, Inc.

The STAR Consortium Awarded $5.3 Million from the Helmsley Charitable Trust to Develop Next Generation Biomarker Tools for Crohn’s Disease Patients The STAR consortium, led by coordinating PI Dr. Rieder, seeks to identify and develop novel biomarkers to help establish effective therapeutics for Crohn’s disease patients with fibrosis.

A research team led by Jae Jung, PhD, Director of the Global Center for Pathogen & Human Health Research, has uncovered the critical role a viral gene, ORF8, plays in infection and disease outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This is the first published study using samples from the COVID-19 registry of the Cleveland Clinic BioRepository.

First Research Published Using Cleveland Clinic’s COVID-19 Study Samples Provides Glimpse into Potential New Treatments Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.

A Cleveland Clinic research team led by Charis Eng, MD, PhD, has conducted a multicenter cohort study to characterize dermatologic (skin) findings associated with PTEN hamartoma tumor syndrome (PHTS), a spectrum of rare genetic disorders. PHTS impacts multiple organ systems and can result in a wide range of clinical outcomes, such as certain cancers, autism spectrum disorder (ASD) and dermatologic features, including growths and lesions.

Characterizing Dermatologic Findings in PTEN Hamartoma Tumor Syndrome Dr. Eng and colleagues conducted a multi-center analysis of skin findings in patients with PTEN hamartoma tumor syndrome.

In a new study published in npj Genomic Medicine, led by Charis Eng, MD, PhD, has found that distinct metabolite profiles may be associated with either cancer or autism spectrum disorder (ASD) and/or developmental delay (DD) in individuals with PTEN mutations.

Metabolites May Influence Cancer Versus Autism Risk in PTEN Hamartoma Tumor Syndrome Dr. Eng’s team found that distinct metabolite profiles may be associated with either cancer or autism spectrum disorder and/or developmental delay in individuals with PTEN hamartoma tumor syndrome.

Cleveland Clinic BME researcher Paul Marasco's work engineering a bionic arm that allows wearers to function like a person without an amputation has been honored by the Clinical Research Forum.

BME Researcher Receives Award from the Clinical Research Forum for Pioneering Bionic Arm Study Dr. Marasco was honored for engineering a prosthetic that allows the wearer to “think” and function like an able-bodied person.

According to a recent study published in Neurology, an international team of researchers co-led by the Lerner Research Institute has developed and validated a prediction model to aid in the early diagnosis of Dravet syndrome, a severe epilepsy characterized by drug-resistant seizures, intellectual disability and high mortality that begins in infancy.

Prediction Model Aids in the Early Diagnosis of Dravet Syndrome Dr. Lal and colleagues have developed a statistical model that integrates genetic and clinical data to calculate the probability of developing Dravet syndrome.

Cleveland Clinic researchers have received two grants from the National Institute of Neurological Disorders & Stroke to investigate potential causes of multiple sclerosis, an autoimmune disease that affects the central nervous system (brain and spinal cord).

Cleveland Clinic Researchers Receive Two Grants to Study Pathogenesis of Multiple Sclerosis Dr. Dutta is collaborating with other Cleveland Clinic researchers to explore possible novel causes of disease progression in multiple sclerosis, as well as potential therapeutic targets.

A Cleveland Clinic research team has developed a new model that may aid in the prediction of which melanoma patients will respond to immune checkpoint inhibitor therapy, a type of immunotherapy that stops “checkpoint” proteins from turning off the immune response against cancer cells.

New Model May Predict Immunotherapy Response in Melanoma Patients Dr. Gastman’s team found that high levels of a CD8 T-cell subpopulation may predict immune checkpoint inhibitor therapy resistance in melanoma.

Cleveland Clinic is one of four institutions in the nation to receive a grant from the National Institutes of Health that provides training for early career investigators treating patients with kidney and benign urinary and blood conditions.

NIH Funds Multi-Institutional Training Network to Support Kidney, Urologic and Hematologic Research Drs. Sedor and Boron are leading a collaboration of Cleveland biomedical institutions to address gaps in community health and training

Cleveland Clinic has developed a “readmission risk score” instrument that consistently predicts the risk of patient readmission to the hospital.

Cleveland Clinic Model Predicts the Risk of Hospital Readmissions Dr. Misra-Hebert and colleagues assessed a Cleveland Clinic model’s ability to predict the likelihood that a patient would need to be readmitted to the hospital within 30 days of discharge.

Cleveland Clinic 2022 Top 10 Medical Innovations list unveils advancements that will transform healthcare/including the next generation of mRNA vaccinology & a new treatment to reduce LDL cholesterol.

Cleveland Clinic unveils top 10 medical innovations with the power to change healthcare in 2022 Topping the list is the next generation of mRNA vaccinology.

Registration is now open for 2022 Bike to Cure benefitting VeloSano – 100% of funds raised support cancer research at Cleveland Clinic. Registration fees are reduced through February 26.

Registration Open for 2022 Bike to Cure Benefiting VeloSano 100% of funds raised support cancer research at Cleveland Clinic; registration fees reduced through Feb. 26 for routes 25 miles or longer

LEARN HOW FAMILY HISTORY PLAYS A ROLE IN YOUR RISK FOR DEVELOPING HEART DISEASE

Thirty-four percent of Americans surveyed believe there is nothing they can do to prevent heart disease if it runs in their family. However, early prevention, regular checkups, and adjusting your lifestyle may help prevent heart disease?
https://youtu.be/x3EOQhd6Wcg

Does Family History Affect Your Risk of Developing Heart Disease? To learn more about family histories effect on heart disease, please visit https://cle.clinic/3rfECKX and the survey results can be found at https://cle.clin...

Dr. Asosingh’s team developed new Shared Resource Laboratory guidelines to ensure experimental success and accuracy.

https://tinyurl.com/2p87ycz3

Lerner-Developed Flow Cytometry Best Practices Lay Groundwork for Global Recommendations Dr. Asosingh’s team developed new Shared Resource Laboratory (SRL) guidelines, including user consultations, to ensure experimental success and accuracy.

In a collaborative study, researchers from Lerner Research Institute’s Infection Biology Program and the Cleveland Clinic Global Center for Pathogen & Human Health Research seek to understand how COVID-19 infection affects pregnant mothers and their children.

https://tinyurl.com/2p877d5v

COVID-19 Infection During Pregnancy Leads to Distinct Immune Changes in Mothers and Babies Dr. Jung’s team studied blood samples collected from mothers with COVID-19 and their infant children who were exposed to SARS-CoV-2 to understand how infection modulates the expression of different inflammatory molecules.

A Cleveland Clinic-led study has revealed new insights into how a diet rich in red meat increases risk for cardiovascular disease. The findings build on more than a decade of research by lead author Stanley Hazen, MD, PhD.

https://tinyurl.com/3rx36w2d

Researchers Probe Further Into Link between Red Meat and Cardiovascular Disease Risk Dr. Hazen identified the gbu gene cluster as a potential therapeutic target for diet-associated cardiovascular disease, and showed that dietary modifications may also help reduce risk.

Age-specific immune and inflammatory responses may help explain why the risk for severe COVID-19 increases with age according to a new Cleveland Clinic study. The findings point to specific immuno-inflammatory factors that could be therapeutically targeted to reduce morbidity and mortality in older COVID-19 patients.

https://tinyurl.com/3amwdku4

Investigating Age Differences in COVID-19 Immune Response Dr. Cheng’s team identified several differences in immune and inflammatory responses that may help explain the elevated risk for severe illness and death observed in older COVID-19 patients.

A research team led by Thaddeus Stappenbeck, MD, PhD, chair, Department of Inflammation & Immunity, has uncovered a new healing mechanism that drives cellular repair in tissues damaged by disease, like the intestines in patients with Crohn’s or celiac disease. https://tinyurl.com/5n8fm3uu

Adaptive Differentiation Drives Cell Repair in Diseased Tissues Dr. Stappenbeck’s group found a new cell type that is produced by intestinal epithelial stem and progenitor cells and provides rapid structural support to damaged, high-turnover tissue and a foundation for its proper healing.

Two Department of Cancer Biology researchers have together received a five-year, $2.7 million grant from the National Institute of Neurological Disorders & Stroke to investigate new treatments for glioblastoma. Glioblastoma is the most common primary malignant brain tumor. https://tinyurl.com/er7ht89j

NIH Funds Collaborative Study into Mechanisms of Glioblastoma Treatment Resistance Drs. Yu and Zhao will study the role of a long non-coding RNA called Lucat1 in glioma stem cells in the search for new therapeutics to help treat glioblastoma and overcome treatment resistance.

Congratulations to Paul Fox, PhD and colleagues on winning a grant to study mechanisms of SARS-CoV-2 (the virus that causes COVID-19) gene regulation and investigate novel targets for new antiviral therapies to treat or prevent COVID-19. The project will be a collaboration between Dr. Fox’s lab and researchers from Cleveland Clinic’s Florida Research & Innovation Center
-2 https://tinyurl.com/yt37777e

Researchers to Study if Non-Coding SARS-CoV-2 Genetic Material Can Offer Insights into New COVID-19 Therapies Led by Dr. Fox, researchers from Cleveland and Florida will collaborate to investigate if certain regions of SARS-CoV-2 genetic material, called non-coding RNA, can be targeted to treat or prevent COVID-19 infection.

A new Cleveland Clinic-led study has identified sildenafil, an FDA-approved therapy for erectile dysfunction (Vi**ra) and pulmonary hypertension (Revatio), as a promising drug candidate to help prevent and treat Alzheimer’s disease (AD).

https://www.lerner.ccf.org/news/details/?Harnessing+Endophenotypes+for+Alzheimer%E2%80%99s+Disease+Drug+Repurposing&76a77dde946648f22990f170b9414613b9b8c440&48b73ec132819095396f4eb49f0c61ddc71c2b58

Harnessing Endophenotypes for Alzheimer’s Disease Drug Repurposing Dr. Cheng’s team developed an endophenotype-based drug repurposing methodology that identified the FDA-approved drug sildenafil as a candidate for the prevention and treatment of Alzheimer’s disease.

coverage of Drs. Tuohy & Budd's phase I clinical trials to vaccine patients against shows how breast cancer can impact indivdual families.
https://tinyurl.com/3pu643a5

Potential breast cancer vaccine undergoing testing The key protein for a potential vaccine that would treat breast cancer was found through "a matter of luck and tenacity."

Hospitals across Ohio have more COVID-19 patients in their ERs and ICUs than ever. The overwhelming majority are unvaccinated. This is preventable. Get vaccinated and get your booster. And keep social distancing, washing your hands, and masking up.

Please share this message.